Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator

< 0.05). TTP399 did not cause hypoglycemia, had no detrimental effect on plasma lipids or liver enzymes, and did not increase blood pressure, highlighting the importance of tissue selectivity and preservation of physiological regulation when targeting key metabolic regulators such as GK.